868P Phase II trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Year: 2024
Type: article
Source: Annals of Oncology
Institutions: Memorial Sloan Kettering Cancer Center, Washington University in St. Louis, Christiana Hospital, Northwestern University, Norton Healthcare, Huntsman Cancer Institute, Oregon Health & Science University, BioAtla (United States), University of Southern California, USC Norris Comprehensive Cancer Center
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Gilead Sciences, Celgene, Memorial Sloan-Kettering Cancer Center, Northwestern University, Exelixis, Celldex Therapeutics, National Comprehensive Cancer Network, Tizona Therapeutics, BeiGene, Seagen, Coherus Biosciences, York University, Eisai, Astellas Pharma, Ipsen, Genentech, Medical Center, University of Pittsburgh, Robert H. Lurie Comprehensive Cancer Center, National Cancer Institute, Daiichi Sankyo Europe
OpenAlex ID: W4402560833